Skip to main content
Erschienen in: Lasers in Medical Science 1/2024

01.12.2024 | Review Article

Definition of refractory melasma and its treatment: a review

verfasst von: Huiyi Yao, Sihao Shen, Xingyue Gao, Jiangfeng Feng, Xiuzu Song, Wenzhong Xiang

Erschienen in: Lasers in Medical Science | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Although patients with refractory melasma have been treated using various methods, there is still no precise definition or summary of the therapies. To define refractory melasma and conduct a review of the treatments, we searched for relevant publications in PubMed, Web of Science, and the Cochrane Library, and a total of 35 references were obtained. Refractory melasma can be roughly defined as an ineffective treatment for melasma, including topical bleaching agents, chemical peels, laser therapy, microdermabrasion for more than six months, or chemical peels treated more than six times. Meanwhile, physicians should be careful when treating patients with darker skin and dermal or mixed types of melasma since these individuals do not respond well to treatment. Lasers combined with other methods, especially different types of lasers or topical agents, are considered more effective than monotherapy. Oral tranexamic acid (TXA) is a prospective cure for refractory melasma. Other methods include a combination of chemical peels, microneedling, or injections with additional therapies. In conclusion, we were able to provide a rough definition of refractory melasma and list the available therapies. According to the literature, the most prevalent treatment is laser combination therapy. However, laser treatment should be considered only after topical agents and chemical peeling have failed. Considering its side effects, efficacy, and safety, oral TXA may be a better option, but more research is needed to make a firm conclusion. Moreover, maintenance therapy is required after treatment.
Literatur
12.
16.
Zurück zum Zitat Wanitphakdeedecha R, Sy-Alvarado F, Patthamalai P, Techapichetvanich T, Eimpunth S, Manuskiatti W (2020) The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study. Lasers Med Sci 35:2015–2021. https://doi.org/10.1007/s10103-020-03045-8CrossRefPubMed Wanitphakdeedecha R, Sy-Alvarado F, Patthamalai P, Techapichetvanich T, Eimpunth S, Manuskiatti W (2020) The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study. Lasers Med Sci 35:2015–2021. https://​doi.​org/​10.​1007/​s10103-020-03045-8CrossRefPubMed
18.
Zurück zum Zitat Beyzaee AM, Goldust M, Rokni GR, Patil A, Mostaghiman R, Golpour M (2023) Comparative effectiveness and safety of topical methimazole 5% monotherapy versus combination of Q-Switched nd: YAG Laser and topical methimazole 5% in patients with refractory melasma. J Cosmet Dermatol. https://doi.org/10.1111/jocd.15641CrossRefPubMed Beyzaee AM, Goldust M, Rokni GR, Patil A, Mostaghiman R, Golpour M (2023) Comparative effectiveness and safety of topical methimazole 5% monotherapy versus combination of Q-Switched nd: YAG Laser and topical methimazole 5% in patients with refractory melasma. J Cosmet Dermatol. https://​doi.​org/​10.​1111/​jocd.​15641CrossRefPubMed
26.
Zurück zum Zitat Zamanian A, Behrangi E, Hossein Ghafarpour G, Mehran G, Espahbodi R, Hoseinzade Fakhim T et al (2015) Effect of hydroquinone plus neodymium-doped yttrium aluminium garnet laser with and without CO2 fractional laser on resistant dermal melasma. J Skin Stem Cell 2. https://doi.org/10.17795/jssc30290CrossRef Zamanian A, Behrangi E, Hossein Ghafarpour G, Mehran G, Espahbodi R, Hoseinzade Fakhim T et al (2015) Effect of hydroquinone plus neodymium-doped yttrium aluminium garnet laser with and without CO2 fractional laser on resistant dermal melasma. J Skin Stem Cell 2. https://​doi.​org/​10.​17795/​jssc30290CrossRef
29.
Zurück zum Zitat Hantash BM, Jimenez F (2009) A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol 8:732–735PubMed Hantash BM, Jimenez F (2009) A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol 8:732–735PubMed
39.
Zurück zum Zitat Ramírez-Oliveros JF, de Abreu L, Tamler C, Vilhena P, de Barros MH (2020) Microneedling with drug delivery (hydroquinone 4% serum) as an adjuvant therapy for recalcitrant Melasma. Skinmed 18:38–40PubMed Ramírez-Oliveros JF, de Abreu L, Tamler C, Vilhena P, de Barros MH (2020) Microneedling with drug delivery (hydroquinone 4% serum) as an adjuvant therapy for recalcitrant Melasma. Skinmed 18:38–40PubMed
40.
Metadaten
Titel
Definition of refractory melasma and its treatment: a review
verfasst von
Huiyi Yao
Sihao Shen
Xingyue Gao
Jiangfeng Feng
Xiuzu Song
Wenzhong Xiang
Publikationsdatum
01.12.2024
Verlag
Springer London
Erschienen in
Lasers in Medical Science / Ausgabe 1/2024
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-024-04066-3

Weitere Artikel der Ausgabe 1/2024

Lasers in Medical Science 1/2024 Zur Ausgabe